The launch of a company from its new partnership with Bristol-Myers Squibb Co. (NYSE: BMY) wasn’t the only big development this week from BioMotiv, the Cleveland biotechnology accelerator associated with the $340 million Harrington Project for Discovery & Development.
Ronald G. Harrington, chair of the BioMotiv board of managers, wrote in an email to stakeholders on Wednesday, Feb. 5, that Satish Jindal, Ph.D., has been named CEO of BioMotiv.
Click here to read the complete article.
Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Originally published February 5, 2020.